-+ 0.00%
-+ 0.00%
-+ 0.00%

Cingulate wins first US patent for ADHD drug CTx-1301, exclusivity to December 2042

PUBT·06/16/2026 12:02:49
Listen to the news
Cingulate wins first US patent for ADHD drug CTx-1301, exclusivity to December 2042
  • Cingulate won its first company-owned U.S. patent covering lead ADHD candidate CTx-1301, a dexmethylphenidate HCl tablet using its timed-release platform.
  • USPTO issued U.S. Patent No. 12,653,791 on June 16, 2026, extending U.S. exclusivity protection through December 2042.
  • Patent covers formulation, tablet structure, release design, and method-of-treatment claims for a trimodal tablet designed to deliver three release phases from one dose.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cingulate Inc. published the original content used to generate this news brief on June 16, 2026, and is solely responsible for the information contained therein.